According to a new market research report titled, ‘Microbubbles/Ultrasound Contrast Agents Market by Application (Diagnostic Imaging [Cardiovascular, Renal, Abdominal, Breast] Therapeutics) Type (Lipid, Protein, Polymer) End User (Hospitals & Clinics, Diagnostics Laboratories)- Global Forecast to 2030,’ published by Meticulous Research®, the microbubbles/ultrasound contrast agents’ market is projected to reach $1.95 billion by 2030, at a CAGR of 15.2% from 2023 to 2030.
Download Free Sample Report Now: https://www.meticulousresearch.com/download-sample-report/cp_id=3732?utm_source=blog&utm_medium=social&utm_campaign=product&utm_content=07-07-2023.
Ultrasound contrast agents are gas-filled microbubbles that
are used to improve the capabilities of diagnostic imaging. They play an
important role in ultrasound imaging and ultrasound-mediated therapy.
Microbubble contrast agents are giving new avenues for therapeutic applications
of ultrasound in drug delivery, gene therapy, and thrombolysis.
The report also includes an extensive assessment of the key
strategic developments of leading market participants in the industry in the
last three to four years. The global microbubbles/ultrasound contrast agents
market has witnessed several strategic developments in recent years.
The high demand for image & diagnostics-guided procedures,
the growing aging population, coupled with the rising prevalence of chronic
diseases, technological advances in ultrasound imaging, and favorable
reimbursement policies for contrast-enhanced procedures are driving the growth
of this market. In addition, increasing microbubbles/ultrasound contrast
agents-related research activities will likely offer better opportunities for
market growth. However, the complexity involved in contrast-enhanced Ultrasound
(CEUS) is expected to restrain the market's growth to some extent.
Aging Population Coupled with the Increasing Prevalence of
Chronic Diseases to Drive the Demand for Microbubbles/Ultrasound Contrast
Agents
Chronic diseases such as cardiovascular diseases,
osteoarticular problems, sleep and mobility disorders, diabetes, and chronic
ischemic heart disease is a major and common concern among the elderly
population. They can lead to limitations in mental and physical abilities,
hospitalization, and increased healthcare expenditures.
Osteoporosis is a common condition in the elderly population
that can be detected using ultrasound. However, chronic diseases such as
diabetes and cardiovascular disease can also affect bone health and may lead to
false-positive results on ultrasound. Thus, it is important to consider the
presence of chronic diseases in the elderly population when interpreting the
ultrasound results.
Have Any Query? Ask To Analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=3732?utm_source=blog&utm_medium=social&utm_campaign=product&utm_content=07-07-2023.
According to the World Population Ageing 2020 report
released by the Department of Economic and Social Affairs, United Nations,
globally, there were 727 million people aged 65 or above in 2020. It is
estimated that by 2050 this number will reach 1.5 billion.
The aging population drives a rise in the number of people
suffering from chronic diseases. Having an ultrasound near the bed is incredibly
useful to older people who cannot move easily or may be anxious to travel to
another setting. This increases the demand for ultrasound procedures for older
adults. Ultrasound technology can be used for evaluating several disorders,
such as bone health and diagnosing heart disease, which may lead to an
increased demand for ultrasound in the geriatric population.
Hence, the aging population will likely increase the demand
for microbubbles/ultrasound contrast agents due to growing utilization, the rising
prevalence of chronic diseases, and the increased demand for healthcare
services.
Microbubbles/Ultrasound Contrast Agents Market: Outlook
The microbubbles/ultrasound contrast agents market is
segmented by type [lipid microbubbles, protein microbubbles, polymer
microbubbles], application [diagnostics imaging {cardiovascular imaging, renal
imaging, abdominal imaging, breast imaging, other diagnostics imaging
applications}, therapeutic applications], end user (hospitals & clinics,
diagnostics laboratories, other end users], and geography (North America,
Europe, Asia-Pacific, Latin America, and Middle East & Africa).
Based on type, the microbubbles/ultrasound contrast agents
market is segmented into lipid microbubbles, protein microbubbles, and polymer
microbubbles. The lipid microbubbles segment is expected to account for the
largest share of the market in 2023. Lipid-based microbubbles ultrasound
imaging with contrast agents has become an essential tool in clinical
diagnostics. It is applied in drug delivery systems which are the materials
working for soft synthetic shells. These lipid shells offer several ways to
support additional functions over increased contrast, such as
minimally-invasive detection of biochemical signatures. Additionally, improved
ultrasound imaging technology and safety & security support the largest
share of the segment.
Quick Buy – Microbubbles/Ultrasound Contrast Market-
Global Opportunity Analysis and Industry Forecast (2023-2030), Research Report:
https://www.meticulousresearch.com/Checkout/23012734?utm_source=blog&utm_medium=social&utm_campaign=product&utm_content=07-07-2023
Based on application, the microbubbles/ultrasound contrast
agents market is segmented into diagnostics imaging and therapeutic
applications. Diagnostic imaging is expected to account for the largest share
of the microbubbles/ultrasound contrast agents market in 2023. The large market
share of this segment is attributed to the technological developments in
specialized application modalities, increasing awareness among people regarding
early diagnosis, and the rising prevalence of chronic diseases, including
cardiovascular diseases such as heart failure and coronary artery disease are
the major causes of premature death every year. For instance, according to the
Centers for Disease Control and Prevention, in 2020, about 523 million people
had some form of cardiovascular disease and nearly 19 million deaths were
caused globally.
Based on end user, in 2023, the hospitals & clinics
segment is expected to account for the largest share of the
microbubbles/ultrasound contrast agents market. People prefer visiting
hospitals for treatment as hospitals or clinics have well-established
infrastructure. Most people regained the accessibility of healthcare facilities
and started visiting hospitals for routine checkups or testing, contributing to
the large market share of the segment.
Based on geography, the microbubbles/ultrasound contrast
agents market is segmented into North America, Europe, Asia-pacific, Latin America,
and Middle East & Africa. In 2023, North America is expected to account for
the largest share of the microbubbles/ultrasound contrast agents market. The
large market share of this segment is primarily due to the aging population and
increasing prevalence of chronic diseases, advanced healthcare systems in the
U.S. and Canada, accelerated growth of economies and high adoption of advanced
technologies.
Some of the key players operating in the
microbubbles/ultrasound contrast agents market are Lantheus Holdings, Inc.
(U.S.), GE HealthCare Technologies Inc. (U.S.), Bracco S.p.A. (Italy),
Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company, Limited (Japan),
nanoPET Pharma GmbH (Germany), Leriva (Greece), Siemens Healthineers AG
(Germany), Bayer AG (Germany), and Fujifilm Holdings Corporation (Japan).
No comments:
Post a Comment